CPA2
Carboxypeptidase A2
Also known as: CBPA2_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P48052
- Gene
- CPA2
- Ensembl
- ENSG00000158516
- Chromosome
- 7
- Canonical length
- 419 aa
- Protein class
- Enzymes, Metabolic proteins, Predicted secreted proteins
- Subcellular location
- Golgi apparatus
- Secretome location
- Secreted to digestive system
OverviewNCBI Gene
Three different forms of human pancreatic procarboxypeptidase A have been isolated. The encoded protein represents the A2 form, which is a monomeric protein with different biochemical properties from the A1 and A3 forms. The A2 form of pancreatic procarboxypeptidase acts on aromatic C-terminal residues and is a secreted protein. [provided by RefSeq, Dec 2008]
Canonical amino-acid sequenceUniProt
419 residues, UniProt reviewed canonical sequence.
>P48052|CPA2
1 MAMRLILFFG ALFGHIYCLE TFVGDQVLEI VPSNEEQIKN LLQLEAQEHL QLDFWKSPTT
61 PGETAHVRVP FVNVQAVKVF LESQGIAYSI MIEDVQVLLD KENEEMLFNR RRERSGNFNF
121 GAYHTLEEIS QEMDNLVAEH PGLVSKVNIG SSFENRPMNV LKFSTGGDKP AIWLDAGIHA
181 REWVTQATAL WTANKIVSDY GKDPSITSIL DALDIFLLPV TNPDGYVFSQ TKNRMWRKTR
241 SKVSGSLCVG VDPNRNWDAG FGGPGASSNP CSDSYHGPSA NSEVEVKSIV DFIKSHGKVK
301 AFITLHSYSQ LLMFPYGYKC TKLDDFDELS EVAQKAAQSL RSLHGTKYKV GPICSVIYQA
361 SGGSIDWSYD YGIKYSFAFE LRDTGRYGFL LPARQILPTA EETWLGLKAI MEHVRDHPYLocalizationUniProt · AlphaFold · HPA
Whether an antibody against CPA2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.23
- Highest tissue expression
- 42,781 nTPM
Expression across tissuesHPA
Tissue
- pancreas: 42,781 nTPM
- stomach: 103 nTPM
- small intestine: 29 nTPM
- duodenum: 16 nTPM
- spinal cord: 11 nTPM
- ovary: 8 nTPM
Single-cell type
- pancreatic acinar cells: 23,034 nCPM
- parietal cells: 707 nCPM
- pancreatic duct cells: 87 nCPM
- late spermatids: 17 nCPM
- monocytes: 17 nCPM
- gastric chief cells: 12 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- medulla oblongata: 5.6 nTPM
- white matter: 5.5 nTPM
- pons: 3.6 nTPM
- midbrain: 2.2 nTPM
- spinal cord: 2.1 nTPM
- thalamus: 1.9 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.4
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.08
- DepMap mean gene effect
- 0.04
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads CPA2 as an antibody target. Whether an autoantibody or antibody against CPA2 could matter depends on whether native CPA2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
CPA2 is annotated as secreted, so native CPA2 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label CPA2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...